Johnson & Johnson has agreed a $850 million deal to acquire Proteologix that will give it a pair of early-stage bispecific antibodies with immunology applications, including a drug heading for phase 1 ...

See our campus—from right where you are. Explore our campus from wherever you are in the world. You'll get an up-close look at areas such as Sears think[box], the Tinkham Veale University Center, our ...

Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times, The Independent, and Investors Chronicle. Suzanne is a content marketer, writer, ...